Summary
The effect of tetrahydroaminoacridine (THA) on the cerebrospinal fluid (CSF) monoamine metabolites was studied in 22 patients with Alzheimer's disease in an open treatment trial. The CSF monoamine metabolites were assayed at baseline and after 4 weeks' active THA treatment with 100 mg/d. A statistically significant increase in the CSF homovanillic acid (HVA) and in 5-hydroxyindoleacetic acid (5-HIAA) content was found. The increase of the CSF 5-HIAA level correlated significantly with improvement in cognitive tests and in the Instrumental Activities of Daily Living Scale. We conclude that besides its anticholinesterase activity THA enhances also the monoaminergic neurotransmission in the brain and that the clinical improvement during THA treatment may be partly mediated through the monoaminergic system.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adem A, Jossan SS, Oreland L (1989) Tetrahydroaminoacridine inhibits human and rat brain monoamine oxidase. Neurosci Lett 107: 313–317
Adolfsson R, Gottfries C-G, Roos BE, Winblad B (1979) Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br J Psychiatry 135: 216–223
Adolfsson R, Gottfries C-G, Oreland L, Wiberg A, Winblad B (1980) Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. Life Sci 27: 1029–1034
Åhlin A, Nybäck H, Junthe T, Öhman G, Nordgren I (1991) THA in Alzheimer's dementia: clinical, biochemical and pharmacokinetic findings. In: Iqbal K, McLachlan DRC, Winblad B, Wisniewski HM (eds) Alzheimer's disease: basic mechanisms, diagnosis and therapeutic strategies. Wiley, Chichester, pp 522–532
Alhainen K, Riekkinen P Sr, Helkala E-L, Partanen J, Laulumaa V, Reinikainen K, Soininen H, Airaksinen M (1991) The effect of THA on cognitive functions and spectral power EEG in Alzheimer's disease: preliminary results of an open study. In: Iqbal K, McLachlan DRC, Winblad B, Wisniewski HM (eds) Alzheimer's disease: basic mechanisms, diagnosis and therapeutic strategies. Wiley, Chichester, pp 611–619
Bartus RT, Dean RL, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfuntion. Science 217: 408–417
Drukarch B, Leysen JE, Stoof JC (1988) Further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroaminoacridine (THA), an alleged drug for the treatment of Alzheimer's disease. Life Sci 42: 1011–1017
Eagger SA, Levy R, Sahakian BJ (1991) Tacrine in Alzheimer's disease. Lancet 337: 889–892
Folstein MF, Folstein SE, McHugh PR (1975) “Minimental state”: a practical method of grading the cognitive stage of patients for the clinician. J Psychiatr Res 12: 189–198
Gauthier S, Bouchard R, Lamontagne A, Bailey P, Bergmann H, Ratner J, Tesfaye Y, St-Marin M, et al (1990) Tetrahydro-aminoacridine-Lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. N Engl J Med 322: 1272–1276
Gottfries CG (1990) Neurochemical aspects on aging and diseases with cognitive impairment. J Neurochem Res 27: 541–547
Gottfries CG, Gottfries I, Roos BE (1969) The investigation of homovanillic acid in the human brain and its correlation to senile dementia. Br J Psychiatry 115: 563–574
Gottfries CG, Adolfsson R, Aquilonius SM, Carlsson A, Eckernäs SÅ, Nordberg A, Oreland L, Svennerholm L, Wiberg Å, Winblad B (1983) Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). Neurobiol Aging 4: 261–271
Jolkkonen J, Lehtinen M, Soininen H, Sennef C, Riekkinen P (1987) Enhanced monoaminergic neurotransmission by desglycinamide-arginine-vasopressin in human subjects. Neurosci Lett 76: 312–315
Lawton MP, Brody E (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9: 179–186
McEntee WJ, Crook TH (1991) Serotonin, memory, and the aging brain. Psychopharmacology 103: 143–149
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the department of health and human services task force on Alzheimer's disease. Neurology 34: 939–944
Nybäck JH, Nyman H, Schalling D (1987) Neuropsychological test performance and CSF levels of monoamine metabolites in healthy volunteers and patients with Alzheimer's dementia. Acta Psychiatr Scand 76: 648–656
Nybäck H, Nyman H, Blomqvist G, Sjögren I, Stone-Elander S (1991) Brain metabolism in Alzheimer's dementia: studies of11C-deoxyglucose accumulation, CSF monoamine metabolites and neuropsychological test performance in patients and healthy subjects. J Neurol Neurosurg Psychiatry 54: 672–678
Nybäck H, Åhlin A, Gustafson L, Minthon L (1992) Swedish experiences of THA therapy in Alzheimer's disease. In: Becker R, Giacobini E (eds) Cholinergic basis for Alzheimer therapy. Birkhauser, Boston Basel Berlin, pp 216–223
Palmer AM, Bowen DM (1990) Neurochemical basis of dementia of the Alzheimer type: contribution of postmortem and antemortem studies. In: Fowler CJ, Carlsson LA, Gottfries CG, Winblad B (eds) Biological markers in dementia of Alzheimer type. Smidt-Gordon, Nishimura, pp 89–105
Piccinin GL, Finali G, Piccirilli M (1990) Neuropsychological effects of 1-deprenyl in Alzheimer's type dementia. Clin Neuropharmacol 13: 147–163
Reinikainen KJ, Paljärvi L, Halonen T, Malminen O, Kosma V-M, Laakso M, Riekkinen PJ (1988) Dopaminergic system and monoaminergic oxidase-B activity in Alzheimer's disease. Neurobiol Aging 9: 245–252
Reinikainen KJ, Soininen H, Riekkinen PJ (1990) Neurotransmitter changes in Alzheimer's disease: implications to diagnostics and therapy. J Neurosci Res 27: 576–586
Reinikainen KJ, Soininen H, Paljärvi L, Riekkinen PJ Sr (1991) Neurotransmitter markers in the cerebrospinal fluid of patients with histologically verified Alzheimer's disease. In: Iqbal K, McLachlan DRC, Winblad B, Wisniewski HM (eds) Alzheimer's disease: basic mechanisms, diagnosis and therapeutic strategies. Wiley, Chichester, pp 522–532
Riekkinen P Jr, Sirviö J, Jäkälä P, Lammintausta R, Riekkinen P (1990) Effect of alpha2 antagonists and an agonist on EEG slowing induced by scopolamine and lesion of the nucleus basalis. Neuropharmacology 29: 993–999
Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry 141: 1356–1364
Soininen H, Unni L, Shillcutt S (1990) Effect of acute and chronic cholinesterase inhibition on biogenic amines in rat brain. Neurochem Res 15: 1185–1190
Stevens DR, Cotman CW (1987) Excitatory actions of tetrahydro-9-aminoacridine (THA) on hippocampal pyramidal neurons. Neurosci Lett 79: 301–305
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Alhainen, K., Helkala, E.L., Reinikainen, K. et al. The relationship of cerebrospinal fluid monoamine metabolites with clinical response to tetrahydroaminoacridine in patients with Alzheimer's disease. J Neural Transm Gen Sect 5, 185–192 (1993). https://doi.org/10.1007/BF02257673
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02257673